Letrozole Accord Healthcare

Letrozole, the active ingredient in Letrozole Accord Healthcare, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to treat estrogen receptor‑positive breast cancer in postmenopausal women, reducing estrogen synthesis that fuels tumor growth.

GNH USA supplies Letrozole Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Clients benefit from reliable logistics, comprehensive documentation, and responsive technical support throughout the supply chain.

Letrozole acts on estrogen‑dependent breast cancer pathways, providing therapeutic benefit in hormone‑sensitive disease.

- Estrogen receptor‑positive breast cancer in postmenopausal women: reduces estrogen production to inhibit tumor growth. - Adjuvant therapy for early‑stage hormone‑receptor‑positive breast cancer: lowers risk of disease recurrence after surgery. - Metastatic hormone‑receptor‑positive breast cancer: provides disease control by sustained estrogen suppression.

Letrozole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness. - Nausea: mild stomach upset. - Headache: pressure or throbbing pain.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes, hepatic failure. - Bone fractures: increased risk of osteoporosis‑related fractures. - Pulmonary embolism: sudden shortness of breath, chest pain.

When prescribing Letrozole, clinicians should observe several precautionary measures to ensure patient safety. - Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation. - Liver function assessment: perform baseline hepatic enzymes and monitor periodically. - Cardiovascular risk evaluation: review history of thromboembolic events and manage risk factors. - Avoid use in premenopausal women: drug is ineffective and may cause ovarian stimulation. - Review concomitant medications: check for interactions that may alter letrozole exposure. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Letrozole’s metabolism and pharmacodynamics can be affected by several co‑administered medicines.

Major Interactions (Avoid): - Estrogen‑containing hormone therapy: antagonizes letrozole’s estrogen‑lowering effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce plasma concentrations. - Tamoxifen: concurrent use may diminish therapeutic benefit and increase toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may enhance anticoagulant effect, requiring INR monitoring. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may modestly increase letrozole levels. - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for possible increased exposure.